Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stock Price: $820.00

+17.84 (2.22%)

Updated Mar 24, 2023 08:00 PM GMT+0000

Featured app

Invest now

<p>79% of retail CFD accounts lose money</p>

Overview

Financials

Statistics

Profile

Chart

Market Cap	88.16B
Revenue	12.17B
Gross Profit	11.37B
Shares Out	107.51M
EPS (ttm)	38.22
PE Ratio	20.3199
Forward PE	19.8225
Dividend Rate (ttm)	0.0000
Dividend Yield	0.0000

Trading Day	Mar 24
Last Price	$820.00
Previous Close	$802.16
Change ($)	17.84
Change (%)	2.22%
Day's Open	806
Day's Range	801.01 - 824
Day's Volume	1.13M
52 Week Range	538.01 - 824

Your browser does not support the video tag.

About Regeneron

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories.

Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

NASDAQ:REGN stock is currently trading at $820.00 as of 08:00 PM UTC, Mar 24, 2023. Use the financials tab to find out more about Regeneron's key financial metrics and recent earnings reports, or track its share price in real time on the chart tab. If you would like to buy shares in Regeneron, our detailed guide explains how to buy Regeneron stock.

Quick info

Country

Industry

Pharmaceutical Preparation Manufacturing

Sector

Manufacturing

Employees

11,851

CEO

Leonard Schleifer

Address

777 Old Saw Mill River Rd
Tarrytown
New York
10591-6717

Phone

19148477000

Website

www.regeneron.com

Ticker Symbol

REGN

Exchange

NASDAQ Stock Exchange

Reporting Currency

USD

News

JPMorgan sees another 20% upside in Regeneron shares: this is why January 20, 2023

Morgan Stanley just upgraded this large cap biotech stock September 9, 2022

Here is why Checkmate shares surged 300% April 20, 2022

Ari Wald on Regeneron: it’s one of my favourite charts in biotech April 5, 2022

Regeneron beats fourth-quarter estimates February 4, 2022

This biotech stock is a buy despite bearish view from BofA Securities January 5, 2022

Best covid stocks to buy now December 29, 2021

Regeneron Pharmaceuticals is ready for its next strike against Omicron December 16, 2021

Regeneron Pharmaceuticals now offers long-term immunity against COVID-19 November 8, 2021

Top 3 undervalued US biotech stocks to buy before it is too late October 12, 2021

Regeneron Pharmaceuticals, Inc. income statements (2022) (USD)

	August 2022
Total Revenue	2.86B
Cost of Revenue	149.20M
Gross Profit	2.71B
Research & Development	794.30M
Selling General & Admin	476.30M
Operating Expense	1.57B
Operating Income	1.29B
Other Income Expense Net	17.40M
EBIT	1.31B
Interest Income	13.10M
Pretax Income	0.96B
Income Tax	111.10M
Minority Interest	0
Net Income	852.10M
Net Income Basic	852.10M

Regeneron Pharmaceuticals, Inc. income statements (2021) (USD)

	November 2021
Total Revenue	3.45B
Cost of Revenue	238.80M
Gross Profit	3.21B
Research & Development	665.40M
Selling General & Admin	445M
Operating Expense	1.56B
Operating Income	1.89B
Other Income Expense Net	-42M
EBIT	1.85B
Interest Income	14.20M
Pretax Income	1.82B
Income Tax	184.40M
Minority Interest	0
Net Income	1.63B
Net Income Basic	1.63B

Regeneron Pharmaceuticals, Inc. income statements (2020) (USD)

	August 2020	June 2020	March 2020	March 2020
Total Revenue	1.95B	1.95B	1.83B	1.83B
Cost of Revenue	102.50M	334.30M	273.40M	273.40M
Gross Profit	1.85B	1.62B	1.55B	1.55B
Research & Development	722M	663.20M	527.80M	527.80M
Selling General & Admin	348.30M	348.30M	367.30M	367.30M
Operating Expense	1.35B	1.35B	1.17B	1.17B
Operating Income	606.20M	606.20M	659.70M	659.70M
Other Income Expense Net	50.20M	312.70M	8.90M	8.90M
EBIT	656.40M	606.20M	659.70M	659.70M
Interest Income	9.70M	9.70M	6.10M	6.10M
Pretax Income	0.92B	0.92B	668.60M	668.60M
Income Tax	21.60M	21.60M	44M	44M
Minority Interest	0	0	0	0
Net Income	897.30M	897.30M	624.60M	624.60M
Net Income Basic	897.30M	897.30M	624.60M	624.60M

Regeneron Pharmaceuticals, Inc. income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	2.17B	2.05B	1.93B	1.71B
Cost of Revenue	278.20M	279.50M	204.60M	230.20M
Gross Profit	1.89B	1.77B	1.73B	1.48B
Research & Development	628.80M	610.50M	1B	590.80M
Selling General & Admin	586.80M	419.90M	417.30M	410.80M
Operating Expense	1.49B	1.31B	1.62B	1.23B
Operating Income	675.70M	738.50M	315.60M	480M
Other Income Expense Net	214.10M	30M	-90.9M	66.10M
EBIT	675.70M	738.50M	315.60M	480M
Interest Income	6.70M	7.80M	8M	7.70M
Pretax Income	889.80M	768.50M	224.70M	546.10M
Income Tax	97.80M	98.90M	31.60M	85M
Minority Interest	0	0	0	0
Net Income	792M	669.60M	193.10M	461.10M
Net Income Basic	792M	669.60M	193.10M	461.10M

Regeneron Pharmaceuticals, Inc. income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	1.93B	1.66B	1.61B	1.51B
Cost of Revenue	159.96M	145.81M	125.30M	151.26M
Gross Profit	1.77B	1.52B	1.48B	1.36B
Research & Development	558.44M	521.53M	495.65M	462.23M
Selling General & Admin	491.30M	369.23M	364.88M	330.77M
Operating Expense	1.21B	1.04B	0.99B	0.94B
Operating Income	718.10M	626.92M	622.19M	567.23M
Other Income Expense Net	-41.9M	8.94M	33.89M	18.17M
EBIT	718.10M	626.92M	622.19M	567.23M
Interest Income	7.35M	7.49M	6.92M	6.44M
Pretax Income	676.20M	635.86M	656.07M	585.40M
Income Tax	-144.2M	41.21M	104.66M	107.42M
Minority Interest	0	0	0	0
Net Income	820.40M	594.66M	551.41M	477.98M
Net Income Basic	820.40M	594.66M	551.41M	477.98M

Regeneron Pharmaceuticals, Inc. income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	1.58B	1.50B	1.47B
Cost of Revenue	140.25M	141.95M	138.05M
Gross Profit	1.44B	1.36B	1.33B
Research & Development	493.48M	492.03M	474.85M
Selling General & Admin	409.91M	306.77M	306.91M
Operating Expense	1.04B	0.94B	0.92B
Operating Income	538.81M	559.93M	550.31M
Other Income Expense Net	15.96M	5.68M	-24.46M
EBIT	538.81M	559.93M	550.31M
Interest Income	6.04M	6.18M	5.40M
Pretax Income	554.77M	565.61M	525.85M
Income Tax	381.25M	177.29M	138.11M
Minority Interest	0	0	0
Net Income	173.52M	388.32M	387.74M
Net Income Basic	173.52M	388.32M	387.74M

Regeneron Pharmaceuticals, Inc. balance sheet (2022) (USD)

	August 2022
Current Cash	7.57B
Receivables	5.16B
Inventory	2.22B
Current Assets	15.53B
Other Current Assets	583.60M
Short Term Investments	583.60M
Long Term Investments	11.68B
Property/Plant Equipment	3.64B
Good Will	N.A
Intangible Assets	0
Tangible Assets (Net)	20.69B
Other Assets	269.90M
Total Assets	27.21B
Accounts Payable	534.20M
Other Current Liabilities	2.50B
Total Current Liabilities	3.03B
Total Liabilities	6.52B
Long Term Debt	2.70B
Current Long Term Debt	0
Minority Interest	0
Common Stock	107.90M
Treasury Stock	-9B
Retained Earnings	20.79B
Capital Surplus	N.A
Shareholder Equity	20.69B
Other Liabilities	N.A

Regeneron Pharmaceuticals, Inc. balance sheet (2021) (USD)

	November 2021
Current Cash	5.79B
Receivables	5.45B
Inventory	2.05B
Current Assets	13.78B
Other Current Assets	482M
Short Term Investments	482M
Long Term Investments	9.90B
Property/Plant Equipment	3.40B
Good Will	N.A
Intangible Assets	0
Tangible Assets (Net)	17.26B
Other Assets	145.90M
Total Assets	23.67B
Accounts Payable	427M
Other Current Liabilities	2.57B
Total Current Liabilities	3.71B
Total Liabilities	6.41B
Long Term Debt	1.98B
Current Long Term Debt	719M
Minority Interest	0
Common Stock	106.20M
Treasury Stock	-7.41B
Retained Earnings	16.74B
Capital Surplus	N.A
Shareholder Equity	17.26B
Other Liabilities	N.A

Regeneron Pharmaceuticals, Inc. balance sheet (2020) (USD)

	August 2020	June 2020	March 2020	March 2020
Current Cash	3.14B	1.99B	2.21B	2.21B
Receivables	2.81B	2.81B	2.93B	2.93B
Inventory	1.64B	1.64B	1.48B	1.48B
Current Assets	7.86B	7.86B	8.64B	8.64B
Other Current Assets	263.80M	263.80M	226.60M	226.60M
Short Term Investments	263.80M	1.15B	1.80B	1.80B
Long Term Investments	6.57B	2.67B	3.30B	3.30B
Property/Plant Equipment	3.03B	3.03B	2.94B	2.94B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	0	N.A	N.A	N.A
Tangible Assets (Net)	9.06B	9.06B	12.13B	12.13B
Other Assets	175.50M	92.40M	93.10M	93.10M
Total Assets	14.43B	14.43B	15.76B	15.76B
Accounts Payable	380.10M	380.10M	347.80M	347.80M
Other Current Liabilities	1.82B	1.82B	1.71B	1.71B
Total Current Liabilities	3.70B	3.70B	2.06B	2.06B
Total Liabilities	5.37B	5.37B	3.62B	3.62B
Long Term Debt	715.90M	715.90M	715.20M	715.20M
Current Long Term Debt	1.50B	N.A	N.A	N.A
Minority Interest	0	0	0	0
Common Stock	6.26B	106.03M	112.19M	112.19M
Treasury Stock	-6.14B	6.14B	1.07B	1.07B
Retained Earnings	8.90B	8.90B	8B	8B
Capital Surplus	N.A	6.26B	5.21B	5.21B
Shareholder Equity	9.06B	9.06B	12.13B	12.13B
Other Liabilities	N.A	N.A	N.A	N.A

Regeneron Pharmaceuticals, Inc. balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	1.62B	1.38B	1.05B	1.71B
Receivables	2.67B	2.66B	2.46B	2.31B
Inventory	1.42B	1.34B	1.32B	1.21B
Current Assets	7.69B	7.11B	6.65B	6.93B
Other Current Assets	387.10M	226.90M	208.20M	182.20M
Short Term Investments	1.60B	1.49B	1.62B	1.52B
Long Term Investments	3.32B	3.16B	2.93B	2.34B
Property/Plant Equipment	2.89B	2.77B	2.68B	2.61B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	N.A	N.A	N.A	N.A
Tangible Assets (Net)	11.09B	10.50B	9.76B	9.44B
Other Assets	76.60M	94.80M	94.30M	144.30M
Total Assets	14.81B	13.94B	13.17B	12.85B
Accounts Payable	418.10M	335.60M	244M	239.60M
Other Current Liabilities	1.63B	1.43B	1.47B	1.27B
Total Current Liabilities	2.10B	1.77B	1.71B	1.51B
Total Liabilities	3.72B	3.43B	3.42B	3.41B
Long Term Debt	713.90M	712.70M	711.30M	709.90M
Current Long Term Debt	N.A	N.A	N.A	N.A
Minority Interest	0	0	0	0
Common Stock	110.28M	109.72M	109.78M	109.58M
Treasury Stock	739.90M	488.40M	441.80M	444.20M
Retained Earnings	7.38B	6.59B	5.92B	5.73B
Capital Surplus	4.43B	4.39B	4.26B	4.16B
Shareholder Equity	11.09B	10.50B	9.76B	9.44B
Other Liabilities	N.A	N.A	N.A	N.A

Regeneron Pharmaceuticals, Inc. balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	1.47B	1.09B	0.92B	1.02B
Receivables	2.24B	2.20B	2.04B	1.94B
Inventory	1.15B	1.04B	0.93B	820.40M
Current Assets	6.45B	5.72B	4.81B	4.54B
Other Current Assets	243.30M	284.81M	163.60M	155.45M
Short Term Investments	1.34B	1.10B	765.64M	605.46M
Long Term Investments	1.76B	1.87B	2.04B	1.82B
Property/Plant Equipment	2.58B	2.52B	2.46B	2.39B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	N.A	N.A	N.A	N.A
Tangible Assets (Net)	8.76B	7.87B	7.19B	6.57B
Other Assets	127.40M	125.20M	85.67M	78.98M
Total Assets	11.73B	10.81B	9.95B	9.37B
Accounts Payable	218.20M	172.36M	171.91M	207.61M
Other Current Liabilities	1.20B	1.24B	1.16B	1.06B
Total Current Liabilities	1.44B	1.42B	1.33B	1.27B
Total Liabilities	2.98B	2.94B	2.77B	2.81B
Long Term Debt	708.50M	707.20M	705.90M	704.65M
Current Long Term Debt	N.A	N.A	N.A	N.A
Minority Interest	0	0	0	0
Common Stock	109.01M	108.21M	107.96M	107.85M
Treasury Stock	396.40M	396.37M	353.85M	316.24M
Retained Earnings	5.25B	4.43B	3.84B	3.29B
Capital Surplus	3.91B	3.84B	3.71B	3.61B
Shareholder Equity	8.76B	7.87B	7.19B	6.57B
Other Liabilities	N.A	N.A	N.A	N.A

Regeneron Pharmaceuticals, Inc. balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	812.73M	792.07M	744.31M
Receivables	1.97B	1.97B	1.84B
Inventory	726.14M	641.59M	554.32M
Current Assets	4.34B	4.14B	3.86B
Other Current Assets	224.97M	143.76M	193.33M
Short Term Investments	596.85M	586.88M	523.54M
Long Term Investments	1.49B	1.33B	1.06B
Property/Plant Equipment	2.36B	2.27B	2.26B
Good Will	N.A	N.A	N.A
Intangible Assets	N.A	N.A	N.A
Tangible Assets (Net)	6.14B	6.05B	5.52B
Other Assets	77.87M	36.62M	36.96M
Total Assets	8.81B	8.70B	8.11B
Accounts Payable	178.18M	153.95M	151.37M
Other Current Liabilities	0.96B	858.07M	854.41M
Total Current Liabilities	1.14B	1.14B	1.03B
Total Liabilities	2.67B	2.65B	2.59B
Long Term Debt	703.45M	702.32M	701.17M
Current Long Term Debt	N.A	N.A	N.A
Minority Interest	0	0	0
Common Stock	107.62M	107.40M	107.12M
Treasury Stock	316.24M	316.24M	316.24M
Retained Earnings	2.95B	2.77B	2.38B
Capital Surplus	3.51B	3.57B	3.45B
Shareholder Equity	6.14B	6.05B	5.52B
Other Liabilities	N.A	N.A	N.A

Regeneron Pharmaceuticals, Inc. cash flow (2022) (USD)

	November 2022	August 2022
Net Income	1.32B	852.10M
Depreciation	92.60M	74.40M
Changes in Receivables	5.55B	5.16B
Changes in Inventories	2.41B	2.22B
Cash Change	7.02B	7.57B
Cash Flow	628.90M	564.40M
Capital Expenditures	-142.5M	-153.6M
Investments	N.A	N.A
Investing Activity (other)	N.A	N.A
Total Investing Cash Flows	192.30M	-413.9M
Dividends Paid	N.A	N.A
Net Borrowings	-4.77B	-5.45B
Other Financing Cash Flows	N.A	N.A
Cash Flow Financing	-725M	-101.1M
Exchange Rate Effect	N.A	N.A

Regeneron Pharmaceuticals, Inc. cash flow (2021) (USD)

	November 2021
Net Income	1.63B
Depreciation	73.20M
Changes in Receivables	5.45B
Changes in Inventories	2.05B
Cash Change	5.79B
Cash Flow	3.41B
Capital Expenditures	-133.2M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-2.44B
Dividends Paid	N.A
Net Borrowings	-3.57B
Other Financing Cash Flows	N.A
Cash Flow Financing	385.40M
Exchange Rate Effect	N.A

Regeneron Pharmaceuticals, Inc. cash flow (2020) (USD)

	August 2020	June 2020	March 2020
Net Income	897.30M	897.30M	624.60M
Depreciation	114.90M	58.80M	56.10M
Changes in Receivables	-121.9M	121.90M	-261M
Changes in Inventories	160M	-162.6M	-70.8M
Cash Change	-859.2M	-216M	590.40M
Cash Flow	1.64B	0.94B	698M
Capital Expenditures	-300M	-129.9M	-170.1M
Investments	N.A	1.58B	-273.1M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	1.01B	1.45B	-443.2M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	-1.19B	1.50B	N.A
Other Financing Cash Flows	N.A	-416.5M	-155.1M
Cash Flow Financing	-2.28B	-2.61B	335.60M
Exchange Rate Effect	N.A	N.A	N.A

Regeneron Pharmaceuticals, Inc. cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	792M	669.60M	193.10M	461.10M
Depreciation	54.30M	52.90M	52.10M	51M
Changes in Receivables	-12.2M	-204.1M	-150.7M	-62M
Changes in Inventories	-108.3M	-59M	-109.6M	-58.6M
Cash Change	233M	339.30M	-663M	240.80M
Cash Flow	787.40M	557.30M	188.30M	897M
Capital Expenditures	-139M	-121.7M	-94.6M	-74.3M
Investments	-69.7M	-85.3M	-741.4M	-701.8M
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-208.7M	-207M	-836M	-776.1M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	N.A	N.A	N.A	N.A
Other Financing Cash Flows	-147.5M	N.A	-29.8M	-10.7M
Cash Flow Financing	-345.7M	-11M	-15.3M	119.90M
Exchange Rate Effect	N.A	N.A	N.A	N.A

Regeneron Pharmaceuticals, Inc. cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	820.40M	594.66M	551.41M	477.98M
Depreciation	42.76M	35.44M	33.64M	36.36M
Changes in Receivables	-40.26M	-163.7M	-95.32M	30.41M
Changes in Inventories	-106.28M	-99.52M	-93.34M	-88.76M
Cash Change	379.89M	169.97M	-101.62M	206.76M
Cash Flow	728.83M	452.96M	394.57M	618.74M
Capital Expenditures	-85.46M	-106.25M	-112.02M	-79.38M
Investments	-180.45M	-170.46M	-372.96M	-346.04M
Investing Activity (other)	N.A	-10M	N.A	N.A
Total Investing Cash Flows	-265.91M	-286.71M	-484.97M	-425.41M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	N.A	N.A	N.A	N.A
Other Financing Cash Flows	-110.1M	-45.24M	-31.85M	N.A
Cash Flow Financing	-83.03M	3.71M	-11.21M	13.43M
Exchange Rate Effect	N.A	N.A	N.A	N.A

Regeneron Pharmaceuticals, Inc. cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	173.52M	388.32M	387.74M
Depreciation	34.51M	37.72M	35.13M
Changes in Receivables	-2.89M	-126.9M	-95M
Changes in Inventories	-78.55M	-84.1M	-81.8M
Cash Change	20.67M	47.75M	-67.46M
Cash Flow	566.95M	414.83M	-30.57M
Capital Expenditures	-107.66M	-59.65M	-54.85M
Investments	-228.08M	-299.23M	-115.56M
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-335.75M	-358.88M	-170.41M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	N.A	N.A	-7.06M
Other Financing Cash Flows	-223.86M	-46.4M	-31.44M
Cash Flow Financing	-210.54M	-8.2M	133.52M
Exchange Rate Effect	N.A	N.A	N.A